MBK-01
Phase 2Biologic
MBK-01 is one of 6 biologic programs targeting Diverticulitis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Diverticulitis
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Tylenol
KKenvue Brands
Approved
Antibiotic
PfizerPreclinical
Paracetamol
GSKPreclinical
MBK-01
MMikrobiomik Healthcare Company S.L.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diverticulitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MBK-01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details